208 related articles for article (PubMed ID: 14511294)
1. On-demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome.
Steen Carlsson K; Höjgård S; Glomstein A; Lethagen S; Schulman S; Tengborn L; Lindgren A; Berntorp E; Lindgren B
Haemophilia; 2003 Sep; 9(5):555-66. PubMed ID: 14511294
[TBL] [Abstract][Full Text] [Related]
2. Prophylaxis for severe haemophilia: clinical and economical issues.
Fischer K; Van Den Berg M
Haemophilia; 2003 Jul; 9(4):376-81. PubMed ID: 12828671
[TBL] [Abstract][Full Text] [Related]
3. Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome.
Fischer K; van der Bom JG; Molho P; Negrier C; Mauser-Bunschoten EP; Roosendaal G; De Kleijn P; Grobbee DE; van den Berg HM
Haemophilia; 2002 Nov; 8(6):745-52. PubMed ID: 12410642
[TBL] [Abstract][Full Text] [Related]
4. The overall effectiveness of prophylaxis in severe haemophilia.
Panicker J; Warrier I; Thomas R; Lusher JM
Haemophilia; 2003 May; 9(3):272-8. PubMed ID: 12694517
[TBL] [Abstract][Full Text] [Related]
5. The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey.
Biss TT; Chan AK; Blanchette VS; Iwenofu LN; McLimont M; Carcao MD; ;
Haemophilia; 2008 Sep; 14(5):923-30. PubMed ID: 18637844
[TBL] [Abstract][Full Text] [Related]
6. The current status of prophylactic replacement therapy in children and adults with haemophilia.
Ljung R; Gretenkort Andersson N
Br J Haematol; 2015 Jun; 169(6):777-86. PubMed ID: 25819695
[TBL] [Abstract][Full Text] [Related]
7. Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen.
Fischer K; Astermark J; van der Bom JG; Ljung R; Berntorp E; Grobbee DE; van den Berg HM
Haemophilia; 2002 Nov; 8(6):753-60. PubMed ID: 12410643
[TBL] [Abstract][Full Text] [Related]
8. The treatment of haemophilia, including prophylaxis, constant infusion and DDAVP.
Berntorp E
Baillieres Clin Haematol; 1996 Jun; 9(2):259-71. PubMed ID: 8800504
[TBL] [Abstract][Full Text] [Related]
9. Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s.
Fischer K; Steen Carlsson K; Petrini P; Holmström M; Ljung R; van den Berg HM; Berntorp E
Blood; 2013 Aug; 122(7):1129-36. PubMed ID: 23777770
[TBL] [Abstract][Full Text] [Related]
10. [Prevention of joint damage in hemophilic children with early prophylaxis].
Kreuz W; Escuriola Ettingshausen C; Funk M; Pons S; Schmidt H; Kornhuber B
Orthopade; 1999 Apr; 28(4):341-6. PubMed ID: 10335528
[TBL] [Abstract][Full Text] [Related]
11. Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors.
Antunes SV; Tangada S; Stasyshyn O; Mamonov V; Phillips J; Guzman-Becerra N; Grigorian A; Ewenstein B; Wong WY
Haemophilia; 2014 Jan; 20(1):65-72. PubMed ID: 23910578
[TBL] [Abstract][Full Text] [Related]
12. Comparing bleed frequency and factor concentrate use between haemophilia A and B patients.
Nagel K; Walker I; Decker K; Chan AK; Pai MK
Haemophilia; 2011 Nov; 17(6):872-4. PubMed ID: 21342368
[TBL] [Abstract][Full Text] [Related]
13. A comparison of traditional vs. Canadian tailored prophylaxis dosing of prophylactic factor infusions in children with haemophilia A and B in a single hemophilia treatment center.
Dodd C; Watts RG
Haemophilia; 2012 Jul; 18(4):561-7. PubMed ID: 22221939
[TBL] [Abstract][Full Text] [Related]
14. Orthopaedic evaluation in children with severe haemophilia A or B submitted to primary prophylaxis therapy in a coagulopathy treatment centre.
De Podestá Haje D; Ono F; De Oliveira GB; Almeida J; De Paula JC; Batista Neto LV; Silva Barros SB
Haemophilia; 2011 Mar; 17(2):228-32. PubMed ID: 21070500
[TBL] [Abstract][Full Text] [Related]
15. Surgery and survival in birth cohorts with severe haemophilia and differences in access to replacement therapy: The Malmö experience.
Osooli M; Steen Carlsson K; Astermark J; Berntorp E
Haemophilia; 2017 Sep; 23(5):e403-e408. PubMed ID: 28758324
[TBL] [Abstract][Full Text] [Related]
16. Update on treatment regimens: prophylaxis versus on-demand therapy.
Manco-Johnson MJ
Semin Hematol; 2003 Jul; 40(3 Suppl 3):3-9. PubMed ID: 14690062
[TBL] [Abstract][Full Text] [Related]
17. Modelling lifelong effects of different prophylactic treatment strategies for severe haemophilia A.
Fischer K; Lewandowski D; Janssen MP
Haemophilia; 2016 Sep; 22(5):e375-82. PubMed ID: 27353496
[TBL] [Abstract][Full Text] [Related]
18. Low-dose tertiary prophylactic therapy reduces total number of bleeds and improves the ability to perform activities of daily living in adults with severe haemophilia A: a single-centre experience from Beijing.
Hua B; Lian X; Li K; Lee A; Poon MC; Zhao Y
Blood Coagul Fibrinolysis; 2016 Mar; 27(2):136-40. PubMed ID: 26258677
[TBL] [Abstract][Full Text] [Related]
19. Aspects of haemophilia prophylaxis in Sweden.
Ljung RC
Haemophilia; 2002 Mar; 8 Suppl 2():34-7. PubMed ID: 11966851
[TBL] [Abstract][Full Text] [Related]
20. Primary prophylaxis in children with haemophilia.
Coppola A; Di Capua M; De Simone C
Blood Transfus; 2008 Sep; 6 Suppl 2(Suppl 2):s4-11. PubMed ID: 19105503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
